XNASIFRX
Market cap147mUSD
Dec 23, Last price
2.50USD
1D
11.61%
1Q
62.34%
IPO
-83.14%
Name
InflaRx NV
Chart & Performance
P/E
—
P/S
2,242.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.97%
Rev. gr., 5y
%
Revenues
63k
Net income
-43m
L+57.78%
CFO
-38m
L+12.06%
Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 63 | ||||||||
Cost of revenue | 57,679 | 52,982 | 48,379 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (57,615) | (52,982) | (48,379) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (1) | (2,442) | 25 | ||||||
Tax Rate | |||||||||
NOPAT | (57,615) | (50,539) | (48,404) | ||||||
Net income | (42,668) 57.78% | (27,042) -40.77% | (45,655) 34.24% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 56,484 | 2,350 | 65,143 | ||||||
BB yield | -63.07% | -1.71% | -32.87% | ||||||
| Debt | |||||||||
Debt current | 374 | 369 | 366 | ||||||
Long-term debt | 1,866 | 2,344 | 2,499 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 37 | 37 | 35 | ||||||
Net debt | (97,085) | (81,996) | (107,754) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (37,813) | (33,743) | (39,937) | ||||||
CAPEX | (81) | (162) | (38) | ||||||
Cash from investing activities | (17,697) | 19,358 | (25,951) | ||||||
Cash from financing activities | 52,986 | 1,937 | 61,577 | ||||||
FCF | (57,116) | (53,443) | (49,131) | ||||||
| Balance | |||||||||
Cash | 90,272 | 81,808 | 83,412 | ||||||
Long term investments | 9,053 | 2,901 | 27,207 | ||||||
Excess cash | 99,322 | 84,709 | 110,619 | ||||||
Stockholders' equity | (239,012) | (201,460) | (178,080) | ||||||
Invested Capital | 342,750 | 291,203 | 284,829 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 54,940 | 44,208 | 41,630 | ||||||
Price | 1.63 -47.42% | 3.10 -34.87% | 4.76 -5.37% | ||||||
Market cap | 89,552 -34.65% | 137,044 -30.84% | 198,159 45.56% | ||||||
EV | (7,533) | 55,048 | 90,404 | ||||||
EBITDA | (57,048) | (52,385) | (47,709) | ||||||
EV/EBITDA | 0.13 | ||||||||
Interest | 36 | 45 | 25 | ||||||
Interest/NOPBT | |||||||||